checkAd

     883  0 Kommentare Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor - Seite 4





    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novartis International AG via Globenewswire

    HUG#2023315

    --- End of Message ---

    Novartis International AG
    P.O. Box Basel Switzerland

    WKN: 904278;ISIN: CH0012005267;


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen
    Seite 4 von 4

    Verfasst von GlobeNewswire
    Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor - Seite 4 Novartis International AG / Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely …

    Schreibe Deinen Kommentar

    Disclaimer